Akero Therapeutics to Present at the Jefferies Healthcare Conference
31 Maio 2023 - 9:00AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic disease marked by high unmet medical need, today
announced that management will present at the Jefferies Healthcare
Conference Wednesday, June 7, 2023, at 10:30 a.m. (ET) in New York,
NY.
A live webcast of the Company presentation will be
available through the investor relations section of the Company's
website at www.akerotx.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including non-alcoholic steatohepatitis (NASH), a
disease without any approved therapies. Akero's lead product
candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion
protein that has been engineered to mimic the balanced biological
activity profile of native FGF21, an endogenous hormone that
alleviates cellular stress and regulates metabolism throughout the
body. EFX is designed to offer convenient once-weekly subcutaneous
dosing. The consistency and magnitude of observed effects position
EFX to be a potentially best-in-class medicine, if approved, for
treatment of NASH. EFX is currently being evaluated in two Phase 2b
clinical trials: the HARMONY study in patients with pre-cirrhotic
NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with
cirrhotic NASH (F4 fibrosis, compensated). EFX is also being
evaluated in an expansion cohort of the SYMMETRY study, comparing
the safety and tolerability of EFX to placebo when added to an
existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH
(F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in
South San Francisco. Visit akerotx.com and follow us on LinkedIn
and Twitter for more information.
Investor Contact:Christina TartagliaStern
Investor Relations,
Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Akero Therapeutics (NASDAQ:AKRO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024